Duchesnay inc. private company information – bloomberg antiemetics definition

Duchesnay Inc. has announced the recent modification of the formulation and packaging of its Pregvit® and Pregvit® Folic 5 prenatal vitamins, the only prescription multivitamin- mineral supplements available in Canada. The new formulations are higher in vitamin D, a nutrient that promotes healthy skeletal development and helps maintain bone integrity in both mother and foetus. The formulation of Pregvit® and Pregvit® Folic 5 was changed based on Health Canada’s current recommendation of a dietary reference intake of 600 IU (International Units) of vitamin D per day during pregnancy and lactation. Vitamin D content was increased from 250 to 600 IU. The new formulations of Pregvit®and Pregvit® Folic 5, in their new packaging, are available from pharmacist. They do not contain lactose, gluten or tartrazine.


Both products are also certified halal and kosher/kosher for Passover by recognized authorities as mentioned in the booklet. Pregvit® and Pregvit® Folic 5 prenatal multivitamins offer a unique formulation and twice-daily dosing (a pink tablet in the morning and a blue tablet at night), whose primary purpose is to optimize the absorption of the most important nutrients prior to conception and throughout pregnancy and lactation. The formulation reduces side effects, such as gastro-intestinal issues, nausea and constipation. They do not contain lactose, gluten or tartrazine. Both products are also certified halal and kosher/kosher for Passover by recognized authorities as mentioned in the booklet. Pregvit® Folic 5 was designed for women at high risk or who have had a previous pregnancy affected by a neural tube defect, those with a family history of neural tube defects, those who have diabetes or malabsorption disorders (e.g. inflammatory bowel disease), those who take anticonvulsive medications (e.g. valproic acid, carbamazepine) or medications known to decrease folate levels (e.g. methotrexate), or those who, according to their healthcare professional, require a higher dose of Folic acid. Pregvit® and Pregvit® Folic 5 are available by prescription only in Canada. Women who are planning to become pregnant are advised to speak to their healthcare professional to determine which product best meets their needs.

Alliance Pharma plc has signed a licensing and distribution agreement with Duchesnay Inc. for Diclectin, indicated for the treatment of nausea and vomiting of associated with pregnancy. Alliance acquired UK rights to Diclectin in January 2015 and this additional agreement secures rights to launch the product in a further nine EU countries including Germany, France and Italy. Diclectin has a well-established efficacy and safety profile and is regarded as the standard of care for nausea and vomiting of pregnancy in Canada, where it has been used for over 30 years and has been prescribed for more than 30 million women. In 2013, it was approved in the US with an FDA Category A safety rating for drugs used during pregnancy. Sales continue to grow strongly in the US, where it is marketed as Diclegis. Alliance has been progressing Diclectin through the marketing authorisation process in the UK and anticipates the product’s launch in the second half of 2017. It is expected that regulatory approvals for the further European territories will follow around a year later.